(Circulation. 1999;99:1197-1208.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Vasodilator Therapy for Primary Pulmonary Hypertension in Children
Presented at the 68th Scientific Sessions of the American Heart Association, Anaheim, Calif, November 13, 1995, and published in abstract form (Circulation. 1995;92[suppl I]:I-126).
From the Department of Pediatrics, Columbia University, College of Physicians and Surgeons, New York, NY (R.J.B.), and the Department of Medicine, University of Pennsylvania, Philadelphia (G.M., A.P.F.).
Background—This report presents 13 years of experience with vasodilator therapy for primary pulmonary hypertension (PPH) in children. Two eras were involved: between 1982 and 1987, oral calcium channel blockers were the only agents available for long-term therapy; after 1987, prostacyclin (PGI2) has been available for long-term intravenous use.
Methods and Results—Seventy-four children underwent short-term vasodilator testing with intravenous PGI2. Those who manifested pulmonary vasodilation ("acute responders") were treated with oral calcium channel blockers. Until 1987, "acute nonresponders" were treated in the same way as long as they had no serious side effects. When PGI2 became available for long-term administration, all nonresponders, as well as those who failed to improve clinically and hemodynamically on calcium channel blockers, were treated with long-term PGI2. In the 31 responders, calcium channel blockers improved survival compared with the 43 nonresponders (P=0.0002). Survival was also better in 24 PGI2-treated nonresponders compared with 22 nonresponders for whom PGI2 was unavailable (P=0.0005) as well as in all children who failed conventional therapy (n=31; P=0.002).
Conclusions—Long-term vasodilator therapy improves survival in children with PPH. In acute responders, oral calcium channel blockers generally suffice. In both nonresponders to short-term testing and responders who fail to improve on calcium channel blockers, continuous intravenous infusion of PGI2 improves survival.
Key Words: hypertension, pulmonary • prostacyclin • epoprostenol • calcium channels
This article has been cited by other articles:
 |
|
 |
|
  Authors/Task Force Members, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J.-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur. Heart J., October 2, 2009; 30(20): 2493 - 2537. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Gatzoulis, R. Alonso-Gonzalez, and M. Beghetti Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease Eur. Respir. Rev., September 1, 2009; 18(113): 154 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-K. Sun, F.-Y. Lee, J.-J. Sheu, C.-M. Yuen, S. Chua, S.-Y. Chung, H.-T. Chai, Y.-T. Chen, Y.-H. Kao, L.-T. Chang, et al. Early Combined Treatment with Cilostazol and Bone Marrow-Derived Endothelial Progenitor Cells Markedly Attenuates Pulmonary Arterial Hypertension in Rats J. Pharmacol. Exp. Ther., September 1, 2009; 330(3): 718 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Barst, J. S. R. Gibbs, H. A. Ghofrani, M. M. Hoeper, V. V. McLaughlin, L. J. Rubin, O. Sitbon, V. F. Tapson, and N. Galie Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S78 - S84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, R. S. Rosenson, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1573 - 1619. [Full Text] [PDF]
|
|
|
|
 |
|
 Writing Committee Members, V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association Circulation, April 28, 2009; 119(16): 2250 - 2294. [Full Text] [PDF]
|
|
|
|
|
|
M. Beghetti Paediatric pulmonary hypertension: monitoring progress and identifying unmet needs Eur. Respir. Rev., March 1, 2009; 18(111): 18 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S G Haworth and A A Hislop Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006 Heart, February 1, 2009; 95(4): 312 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Hirenallur-S., S. T. Haworth, J. T. Leming, J. Chang, G. Hernandez, J. B. Gordon, and N. J. Rusch Upregulation of vascular calcium channels in neonatal piglets with hypoxia-induced pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, November 1, 2008; 295(5): L915 - L924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S G Haworth The management of pulmonary hypertension in children Arch. Dis. Child., July 1, 2008; 93(7): 620 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E Lammers, A. A Hislop, Y. Flynn, and S. G Haworth Epoprostenol treatment in children with severe pulmonary hypertension Heart, June 1, 2007; 93(6): 739 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Taylor, G. Derrick, A. McEwan, S. G. Haworth, and M. R. J. Sury Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension Br. J. Anaesth., May 1, 2007; 98(5): 657 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Elliott, E. W. Glissmeyer, G. T. Havlena, J. Carlquist, J. T. McKinney, S. Rich, M. D. McGoon, M. B. Scholand, M. Kim, R. L. Jensen, et al. Relationship of BMPR2 Mutations to Vasoreactivity in Pulmonary Arterial Hypertension Circulation, May 30, 2006; 113(21): 2509 - 2515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Maiya, A A Hislop, Y Flynn, and S G Haworth Response to bosentan in children with pulmonary hypertension Heart, May 1, 2006; 92(5): 664 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Kawut, E. M. Horn, K. K. Berekashvili, A. C. Widlitz, E. B. Rosenzweig, and R. J. Barst von Willebrand Factor Independently Predicts Long-term Survival in Patients With Pulmonary Arterial Hypertension Chest, October 1, 2005; 128(4): 2355 - 2362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Rosenzweig, D. D. Ivy, A. Widlitz, A. Doran, L. R. Claussen, D. Yung, S. H. Abman, A. Morganti, N. Nguyen, and R. J. Barst Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension J. Am. Coll. Cardiol., August 16, 2005; 46(4): 697 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ford Pulmonary artery hypertension: new drug treatment in children Arch. Dis. Child. Ed. Pract., June 1, 2005; 90(1): ep15 - ep20. [Full Text] [PDF]
|
|
|
|
|
|
A Rashid and D Ivy Severe paediatric pulmonary hypertension: new management strategies Arch. Dis. Child., January 1, 2005; 90(1): 92 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278. [Full Text] [PDF]
|
|
|
|
 |
|
 B. B. Das, R. R. Wolfe, K.-C. Chan, G. L. Larsen, J. T. Reeves, and D. Ivy High-Altitude Pulmonary Edema in Children With Underlying Cardiopulmonary Disorders and Pulmonary Hypertension Living at Altitude Arch Pediatr Adolesc Med, December 1, 2004; 158(12): 1170 - 1176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.E. Roberts, J.J. McElroy, W.P.K. Wong, E. Yen, A. Widlitz, R.J. Barst, J.A. Knowles, and J.H. Morse BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease Eur. Respir. J., September 1, 2004; 24(3): 371 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Tissieres, L. Nicod, C. Barazzone-Argiroffo, P. C. Rimensberger, and M. Beghetti Aerosolized iloprost as a bridge to lung transplantation in a patient with cystic fibrosis and pulmonary hypertension Ann. Thorac. Surg., September 1, 2004; 78(3): e48 - e50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Yung, A. C. Widlitz, E. B. Rosenzweig, D. Kerstein, G. Maislin, and R. J. Barst Outcomes in Children With Idiopathic Pulmonary Arterial Hypertension Circulation, August 10, 2004; 110(6): 660 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 35S - 62S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. V. McLaughlin, K. W. Presberg, R. L. Doyle, S. H. Abman, D. C. McCrory, T. Fortin, and G. Ahearn Prognosis of Pulmonary Arterial Hypertension*: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 78S - 92S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Galie, W. Seeger, R. Naeije, G. Simonneau, and L. J. Rubin Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 81S - 88S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Eells Advances in Prostacyclin Therapy for Pulmonary Arterial Hypertension Crit. Care Nurse, April 1, 2004; 24(2): 42 - 54. [Full Text] [PDF]
|
|
|
|
|
|
S C Apostolopoulou, S Rammos, Z S Kyriakides, D J Webb, N R Johnston, D V Cokkinos, and D T. Kremastinos Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart disease Heart, October 1, 2003; 89(10): 1221 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W D Carroll and R Dhillon Sildenafil as a treatment for pulmonary hypertension Arch. Dis. Child., September 1, 2003; 88(9): 827 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Widlitz and R.J. Barst Pulmonary arterial hypertension in children Eur. Respir. J., January 1, 2003; 21(1): 155 - 176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. J. Ten Harkel, N. A. Blom, and J. Ottenkamp Isolated Unilateral Absence of a Pulmonary Artery: A Case Report and Review of the Literature Chest, October 1, 2002; 122(4): 1471 - 1477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Coe, S. J. Haleen, K. M. Welch, Y.-A. Liu, and F. Coceani The Endothelin A Receptor Antagonists PD 156707 (CI-1020) and PD 180988 (CI-1034) Reverse the Hypoxic Pulmonary Vasoconstriction in the Perinatal Lamb J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 672 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Barst, S. Rich, A. Widlitz, E. M. Horn, V. McLaughlin, and J. McFarlin Clinical Efficacy of Sitaxsentan, an Endothelin-A Receptor Antagonist, in Patients With Pulmonary Arterial Hypertension* : Open-Label Pilot Study Chest, June 1, 2002; 121(6): 1860 - 1868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Suhara, Y. Sawa, N. Fukushima, K. Kagisaki, C. Yokoyama, T. Tanabe, S. Ohtake, and H. Matsuda Gene transfer of human prostacyclin synthase into the liver is effective for the treatment of pulmonary hypertension in rats J. Thorac. Cardiovasc. Surg., May 1, 2002; 123(5): 855 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. N. Mendeloff, B. F. Meyers, T. M. Sundt, T. J. Guthrie, S. C. Sweet, M. de la Morena, S. Shapiro, D. T. Balzer, E. P. Trulock, J. P. Lynch, et al. Lung transplantation for pulmonary vascular disease Ann. Thorac. Surg., January 1, 2002; 73(1): 209 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Robbins, R. J. Barst, R. N. Channick, and L. J. Rubin Pulmonary vasoreactivity in PPH J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1267 - 1267. [Full Text] [PDF]
|
|
|
|
|
|
R. A. Krasuski and T. M. Bashore Reply J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1268 - 1268. [Full Text] [PDF]
|
|
|
|
|
|
M Beghetti, M Berner, and P C Rimensberger Long term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusion Heart, September 1, 2001; 86(3): e10 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
British Cardiac Society Guidelines and Medical Pra Recommendations on the management of pulmonary hypertension in clinical practice Heart, September 1, 2001; 86(90001): i1 - 13. [Full Text] [PDF]
|
|
|
|
|
|
D Abrams, I Schulze-Neick, and A G Magee Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension Heart, August 1, 2000; 84 (2): e4 - e4. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Ziesche, V Petkov, K Wittmann, J Kopatschka, L Stiebellehner, P Schenk, P Germann, G Röder, R Ullrich, and L H Block Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertension Heart, April 1, 2000; 83(4): 406 - 409. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. P. Fishman Epoprostenol (Prostacyclin) and Pulmonary Hypertension Ann Intern Med, March 21, 2000; 132(6): 500 - 502. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Barst Do No Harm Chest, November 1, 1999; 116(5): 1147 - 1148. [Full Text] [PDF]
|
|